Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1985-04-04
1987-08-04
Brown, Johnnie R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514936, 536 23, A61K 3170, C07H 1700
Patent
active
046846301
ABSTRACT:
A method of parenterally delivering aqueously unstable drugs that includes the aqueous dilution of a stable, anhydrous organic solution having the drug dissolved therein. The resulting organic-aqueous solution is physiologically suitable for parenteral delivery into a warm-blooded mammal and contains the drug in an effective dosage concentration per unit volume.
REFERENCES:
patent: Re28819 (1976-05-01), Thompson
patent: 3070502 (1962-12-01), Sponnoble
patent: 3472931 (1969-10-01), Stoughton
patent: 3551554 (1970-12-01), Herschler
patent: 3833725 (1974-09-01), Thompson
patent: 3998807 (1976-12-01), Moffatt
patent: 4069382 (1978-01-01), Baker et al.
patent: 4330534 (1982-05-01), Sakurai et al.
patent: 4405611 (1983-09-01), Chatterji et al.
Washington, Influences of Parenterally Administered Dimethyl Sulfoxide on Regional Blood Flow, Chem. Abstracts 83:173190d (1974).
Somogyi et al., Dimethyl Sulfoxide (DMSo), A Convenient Solvent of 7,12-Dimethylbenz(9)anthracene for Intravenous Injection, Chem. Abs. 73:69800k (1970).
Ladage et al., Solvent Vehicle for Therapeutics and Pharmaceutical Composition Containing H, Chem. Abstracts 92(2): 11236g (1979).
Haughey et al., Stabilized Oxytetracycline Solutions for Parenteral Administration, Chem. Abstracts 89: 220881r (1978).
Chatterji et al., "Stabilization of 5-Azacytidine by Nucleophilic Addition of Bisulfite Ion,"Journal of Pharmaceutical Sciences, 66(7): 822-826 (1979).
Notari et al., "Kinetics and Mechanisms of Degradation of the Antileukemic Agent 5-Azacytidine in Aqueous Solutions," Journal of Pharmaceutical Sciences, 64(7): 1148-1157 (1975).
Chatterji, "Stability of Azacytidine in Infusion Solutions: Clarification of Conflicting Literature Data," American Journal of Hospital Pharmacy, 39:1638, 1640 (Oct. 1982).
Beisler et al., "Synthesis and Antitumor Activity of 5-Azacytosine Arabinoside," J. Med. Chem., 22:1230-34 (1979), p. 2.
Benjamin et al., "Degradation Mechanism for 5-Azacytidine and Related Compounds in Aqueous Media," Amer. Pharm. Assn., 11:60 (1981), Abstract No. 16, p. 2.
Benjamin, "The Chemistry of the Degradation of 5-Azacytidine and Some Derivatives of 5-Azacytosine," Doctoral Dissertation, The University of Kansas, 1979, pp. 2, 3.
Beisler, "Isolation, Characterization, and Properties of a Facile Hydrolysis Product of the Antitumor Nucleoside, 5-Azacytidine," J. Med. Chem., 21:204-208 (1978), p. 3.
Mojaverian et al., "Development of an Intravenous Formulation or the Unstable Investigational Cytotoxic Nucleosides 5-Azacytosine Arabinoside (NSC 281272) and 5-Azacytidine (NSC 102816)," J. Pharm. Pharmacol., 36:728-733 (1984).
Mojaverian Parviz
Repta Arnold J.
Brown Johnnie R.
Rollins John W.
LandOfFree
Method of parenterally delivering drugs and related compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of parenterally delivering drugs and related compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of parenterally delivering drugs and related compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-883886